TIANFU-CHEM - Soraf...

TIANFU-CHEM - Sorafenib tosylate

TIANFU-CHEM - Sorafenib tosylate

Min.Order / FOB Price:Get Latest Price

1 Gram

FOB Price: USD 1000.0000

  • Min.Order :1 Gram
  • Purity: 99.0%
  • Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram,Other

Keywords

Sorafenib tosylate 475207-59-1 C21H16ClF3N4O3.C7H8SO3

Quick Details

  • Appearance:Solid
  • Application:Organic synthesis
  • PackAge:IN 25kg drums
  • ProductionCapacity:10|Metric Ton|Month
  • Storage:In Room Temperature
  • Transportation:As per MSDS

Superiority:

Henan Tianfu Chemical Co., Ltd. is located in Zhengzhou High-tech Development Zone with import and export license.

We passed ISO 9001:2008 in 2009, and won "High-tech Enterprise" by provincial government in 2013.The objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal.

Improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. We are constantly striving to make Henan Tianfu a leading chemical supplier, and hope to create a better future with you.

Details:

Sorafenib tosylate Basic information
Indications and Usage Mechanisms of Action Clinical Research Adverse reactions
Product Name: Sorafenib tosylate
Synonyms: SORAFENIB TOSYLATE;Sorafenib & its intermediates;Sorafinib mesylate;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;Sorafenib Tosylate(Bay 43-9006,Nexavar);2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate;Sorafenib Tosylate (Nexavar);Sorafenib (Nexavar)
CAS: 475207-59-1
MF: C21H16ClF3N4O3.C7H8SO3
MW: 637.03
EINECS:
Product Categories: Bay 43-9006;Inhibitors;MAPK
Mol File: Mol File
Sorafenib tosylate Structure
Sorafenib tosylate Chemical Properties
CAS DataBase Reference 475207-59-1(CAS DataBase Reference)
Safety Information
Risk Statements 36/37/38
Safety Statements 28-26
MSDS Information
Sorafenib tosylate Usage And Synthesis
Indications and Usage Sorafenib tosylate is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.
Mechanisms of Action Sorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.
Clinical Research In a stage three randomized clinical study of American and European treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. One group received sorafenib tosylate, while the other received a placebo. Mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. The sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. However, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison.
602 advanced liver cancer patients selected from the USA, Europe, Australia, and other countries and areas, who did not receive systematic treatment, were included in a study. Results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.
Adverse reactions Manageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.
Uses Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.
Uses Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively
Uses An inhibitor of Flk-1 (VEGFR), PDGFR and Raf kinases.
Sorafenib tosylate Preparation Products And Raw materials
 

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View